Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MapLight TherapeuticsMPLT -1.19%12 Pretax Margin % is % as of Jun. 2026. GuruFocus rates MPLT with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, MapLight Therapeutics ranks worse than 105932.1% on this metric.
The historical rank and industry rank for MapLight Therapeutics's Pretax Margin % or its related term are showing as below:
MPLT's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -83.71 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
MapLight Therapeutics Pretax Margin % Related Terms
MapLight Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for MapLight Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MPLT vs SRPT, ZYME, ABCL: Pretax Margin % Comparison
For the Biotechnology subindustry, MapLight Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MapLight Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MapLight Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where MapLight Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MapLight Therapeutics (MPLT) has a Pretax Margin % of % as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on MapLight Therapeutics and its competitors. According to the industry distribution chart, MapLight Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry.
Is MapLight Therapeutics' Pretax Margin % too high?
MapLight Therapeutics' current Pretax Margin % is %. Based on the distribution chart, MapLight Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MapLight Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' Pretax Margin % compare to SRPT and ZYME?
According to the Biotechnology industry distribution chart, MapLight Therapeutics ranks #999999 out of 944 companies for Pretax Margin %. This places MapLight Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on MapLight Therapeutics and its competitors. MapLight Therapeutics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current Pretax Margin % of %. The current Pretax Margin % is %. MapLight Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current Pretax Margin % is % as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
12GF Score
Get the complete analysis for MPLT
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MPLT has been successfully added to your 
